NASDAQ$APLT
Applied Therapeutics Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Reported financial results for the second quarter ended June 30, 2023.
Applied Therapeutics reported on their progress in advancing programs across Galactosemia, SORD Deficiency and Diabetic Cardiomyopathy in the second quarter of 2023.
- Continued to advance programs across Galactosemia, SORD Deficiency and Diabetic Cardiomyopathy.
- Efforts will focus on regulatory progress in Galactosemia and SORD Deficiency.
- Phase 3 clinical readouts in SORD Deficiency and DbCM are expected in 2H 2023.
- Commitment to bring govorestat (AT-007) and caficrestat (AT-001) to patients with devastating diseases in need of treatment remains steadfast.
Headline financials
Revenue & EPS history
Applied Therapeutics · Revenue · Quarterly
$10.7M
Forward guidance
The company provided forward-looking statements regarding their plans to request a pre-NDA meeting or submit an NDA or MAA for approval and the anticipated cash runway of the Company.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 12 quarterly earnings reports · overlaid with Q2 2023
-2.6%
Avg return
Earnings day
-9.9%
Avg return
5 days after
-14.9%
Avg return
30 days after
52%
14 / 27 earnings
Positive
+24.0%
Q1 2025
Best reaction
-71.6%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -71.6% | -68.9% | -77.9% | |
| Q2 2025 | +5.6% | +9.1% | -5.6% | |
| Q1 2025 | +24.0% | -22.5% | -26.9% | |
| Q4 2024 | +0.1% | +4.3% | +1.5% | |
| Q3 2024 | +4.6% | +2.7% | -86.8% | |
| Q2 2024 | +5.7% | -4.4% | -6.4% | |
| Q1 2024 | -6.8% | -1.9% | -1.3% | |
| Q4 2023 | +7.3% | +2.6% | -6.2% | |
| Q3 2023 | -12.1% | -10.8% | +34.6% | |
| Q2 2023 | -3.2% | -14.1% | +1.3% | |
| Q1 2023 | -3.6% | -7.3% | -10.9% | |
| Q4 2022 | -5.6% | -7.9% | +6.3% | |
| Q3 2022 | -0.2% | — | — | |
| Q2 2022 | +3.0% | — | — | |
| Q1 2022 | -1.7% | — | — | |
| Q4 2021 | -9.1% | — | — | |
| Q3 2021 | +1.6% | — | — | |
| Q2 2021 | +3.6% | — | — | |
| Q1 2021 | -2.2% | — | — | |
| Q4 2020 | +3.3% | — | — | |
| Q3 2020 | +5.9% | — | — | |
| Q2 2020 | +13.8% | — | — | |
| Q1 2020 | +3.3% | — | — | |
| Q4 2019 | -27.7% | — | — | |
| Q3 2019 | -7.5% | — | — | |
| Q2 2019 | +7.0% | — | — | |
| Q1 2019 | -6.7% | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro